uronid 200 mg comprimidos recubiertos con película
casen recordati s.l. - flavoxato hidrocloruro - comprimido recubierto con pelÍcula - 200 mg - flavoxato hidrocloruro 200 mg - flavoxato
uripax 200 mg tableta recubierta
farmindustria s.a. - clorhidrato de flavoxato; - tableta recubierta - por tableta - flavoxato
linezolid richet
1. rigecin labs s.a.c.i.f.i., buenos aires, argentina. fabricación del producto terminado. 2. laboratorios richet s.a., buenos a - solución para inyección iv - 2 mg/ml
linezolid richet®
rigecin labs s.a.c.i.f.i. - linezolid - solución para inyección iv. - 2 mg/ml
linezolid richet®
laboratorios richet s.a.. - linezolid - comprimido recubierto - 600 mg
flavoxato 200 mg tableta recubierta
ajr labs s.a.c. - droguerÍa - tableta recubierta - por tableta - - flavoxato
zynrelef
heron therapeutics, b.v. - bupivacaine, meloxicam - dolor, postoperatorio - anestésicos - zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.
amikacina normon 500 mg/ 100 ml solucion para perfusion efg
laboratorios normon s.a. - amikacina sulfato - soluciÓn para perfusiÓn - 500 mg - amikacina sulfato 5 mg - amikacina
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - cerdos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
amicacina braun 10 mg/ml solucion para perfusion intravenosa
b braun medical s.a. - amikacina sulfato - soluciÓn para perfusiÓn - 1.000 mg - amikacina sulfato 10 mg - amikacina